• LAST PRICE
    3.2104
  • TODAY'S CHANGE (%)
    Trending Up0.0104 (0.3250%)
  • Bid / Lots
    3.2100/ 6
  • Ask / Lots
    3.2200/ 2
  • Open / Previous Close
    3.1600 / 3.2000
  • Day Range
    Low 3.1600
    High 3.3200
  • 52 Week Range
    Low 0.9400
    High 6.4200
  • Volume
    190,120
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.2
TimeVolumeCRDF
09:32 ET108443.16
09:34 ET13293.19
09:36 ET197503.21
09:39 ET17303.21
09:41 ET10503.21
09:43 ET5003.2
09:45 ET3003.22
09:48 ET2003.2
09:50 ET4003.21
09:52 ET2003.22
09:54 ET4003.22
09:56 ET4113.2488
09:57 ET6003.25
09:59 ET152723.24
10:01 ET4003.23
10:03 ET2003.235
10:06 ET24203.25
10:08 ET31003.2699
10:10 ET2003.25
10:12 ET17233.23
10:14 ET15003.245
10:17 ET12003.2501
10:19 ET2003.255
10:21 ET7003.24
10:24 ET8003.24
10:26 ET1003.25
10:28 ET13003.24
10:30 ET4083.24
10:32 ET6403.25
10:33 ET23003.24
10:35 ET11003.2301
10:37 ET14003.25
10:39 ET29273.24
10:42 ET16333.24
10:44 ET14493.23
10:48 ET5723.24
10:50 ET1003.25
10:51 ET2003.25
10:53 ET21003.2508
10:57 ET1003.26
11:00 ET8403.26
11:11 ET6743.25
11:13 ET1003.25
11:15 ET4503.23
11:20 ET13003.26
11:22 ET4003.26
11:24 ET2003.26
11:26 ET12003.27
11:27 ET7453.27
11:29 ET2313.29
11:31 ET12003.2896
11:33 ET1003.285
11:36 ET10003.28
11:38 ET2003.28
11:40 ET5003.28
11:42 ET3003.28
11:51 ET56253.29
11:54 ET11003.305
11:56 ET1493.3001
11:58 ET4003.31
12:00 ET5003.31
12:03 ET1003.3
12:07 ET3003.31
12:09 ET1003.3
12:12 ET10803.304
12:14 ET1003.3
12:16 ET3023.2812
12:18 ET16103.28
12:20 ET10003.27
12:32 ET15003.28
12:38 ET1003.28
12:39 ET2113.29
12:45 ET5343.28
12:48 ET107353.3
12:52 ET1253.3
12:54 ET10643.31
12:56 ET2003.32
12:57 ET25753.308
12:59 ET1553.305
01:01 ET1003.305
01:03 ET5533.3
01:06 ET10003.3007
01:10 ET66933.28
01:12 ET4003.28
01:14 ET1093.27
01:15 ET14643.27
01:21 ET2003.275
01:24 ET2003.285
01:28 ET2003.2888
01:30 ET1003.29
01:33 ET25553.29
01:35 ET3003.29
01:37 ET22003.28
01:48 ET4003.27
01:53 ET9003.26
01:55 ET18203.27
01:57 ET15003.28
02:00 ET5003.2775
02:02 ET8003.2706
02:04 ET1003.275
02:06 ET3003.2784
02:08 ET1003.28
02:13 ET2163.28
02:15 ET9993.274
02:18 ET17003.26
02:20 ET6653.25
02:26 ET5003.25
02:27 ET8003.2406
02:31 ET14513.24
02:33 ET13003.2401
02:36 ET1003.24
02:42 ET18003.25
02:44 ET3003.24
02:47 ET3103.235
02:54 ET2003.23
02:58 ET1003.235
03:00 ET6003.23
03:02 ET26393.24
03:03 ET8493.22
03:05 ET3843.22
03:12 ET9993.2104
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCRDF
Cardiff Oncology Inc
143.1M
-3.6x
---
United StatesRGLS
Regulus Therapeutics Inc
139.4M
-1.5x
---
United StatesRAPT
RAPT Therapeutics Inc
137.5M
-1.4x
---
United StatesCNTX
Context Therapeutics Inc
150.0M
-1.5x
---
United StatesTVGN
Tevogen Bio Holdings Inc
132.4M
-1,767.7x
---
United StatesGOSS
Gossamer Bio Inc
132.1M
-0.6x
---
As of 2024-05-30

Company Information

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Contact Information

Headquarters
11055 Flintkote AveSAN DIEGO, CA, United States 92121-1220
Phone
858-952-7570
Fax
858-217-4768

Executives

Independent Chairman of the Board
Rodney Markin
Chief Executive Officer, Director
Mark Erlander
Chief Financial Officer
James Levine
Chief Operating Officer
Vicki Kelemen
Chief Scientific Officer
Tod Smeal

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$143.1M
Revenue (TTM)
$610.0K
Shares Outstanding
44.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.89
EPS
$-0.90
Book Value
$1.56
P/E Ratio
-3.6x
Price/Sales (TTM)
234.6
Price/Cash Flow (TTM)
---
Operating Margin
-7,261.15%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.